EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition

Aleksey Chernev iD, Alina Kaurtseva iD, Ruslan Abasov iD, Rafael Enikeev, Nina Gegelia, Gulnara Abdrakova iD, Natalia Usman iD, Alexander Druy iD, Grigory Raskin iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70661 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Aleksey Chernev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Sergey Berezin Medical Institute, St. Petersburg, Russian Federation. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, DNA Polymerase II, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatoid adenocarcinoma of the lung (HAL) is a rare form of lung cancer with histological and morphological properties of hepatocellular carcinoma, characterized by an aggressive course of the disease and unfavorable prognosis. Given the rarity of the pathology and the lack of unambiguous therapeutic protocols, descriptions of clinical cases of HAL deserve attention. Case We describe a case of metastatic HAL in a 61‐year‐old patient, harboring a mismatch repair deficiency associated with the loss of PMS2 protein expression. Molecular‐genetic study identified several oncogenic variants including PMS2 p.Arg421Ter, PMS2 p.Arg107Trp, and POLE p.Pro286Arg and confirmed their somatic status. The laboratory findings clinically justified the use of immunotherapy with pembrolizumab, which afforded stabilization of the disease according to computed tomography data and complete tumor response according to morphological examination data.

Conclusion

The presented case highlights the room for immunotherapy in the highly aggressive HAL. The POLE p.Pro286Arg missense mutation has been attributed as a predictor for immune checkpoint inhibition efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmune Checkpoint InhibitorsDNA Polymerase IIAntibodies, Monoclonal, HumanizedAdenocarcinoma of LungHumansMiddle AgedMaleLiver NeoplasmsMutation, MissenseTomography, X-Ray ComputedPoly-ADP-Ribose Binding Proteins

Stichwörter der Autor:innen

POLE p.Pro286Arg mutationhepatoid adenocarcinoma of the lungimmunotherapymismatch repair deficiency

Substanzen

Immune Checkpoint InhibitorspembrolizumabDNA Polymerase IIAntibodies, Monoclonal, HumanizedPOLE protein, humanPoly-ADP-Ribose Binding Proteins

Autor:innen und Institutionen

  • Dr. Sergey Berezin Medical Institute, St. Petersburg, Russian Federation.
  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.

ORCID-Profile: Aleksey Chernev, Alina Kaurtseva, Ruslan Abasov, Gulnara Abdrakova, Natalia Usman, Alexander Druy, Grigory Raskin

Zitieren

APA

Chernev, A., Kaurtseva, A., Abasov, R., Enikeev, R., Gegelia, N., Abdrakova, G., Usman, N., Druy, A., & Raskin, G. (2026). A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition. Cancer Reports. https://doi.org/10.1002/cnr2.70661

Vancouver

Chernev A, Kaurtseva A, Abasov R, Enikeev R, Gegelia N, Abdrakova G, et al. A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition. Cancer Reports. 2026. doi:10.1002/cnr2.70661

BibTeX
@article{Chernev2026,
  author = {Chernev, Aleksey and Kaurtseva, Alina and Abasov, Ruslan and Enikeev, Rafael and Gegelia, Nina and Abdrakova, Gulnara and Usman, Natalia and Druy, Alexander and Raskin, Grigory},
  title = {A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70661}
}
Kostenlos starten →